Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FOLD Amicus Therapeutics	$5.65 -1.5%	$6.40	$5.63 ▼ $12.65	$1.74B	0.54	3.08 million shs	2.50 million shs
MBX MBX Biosciences	$9.73 -5.4%	$10.70	$4.81 ▼ $27.50	$325.22M	N/A	249,968 shs	201,379 shs
MRUS Merus	$53.06 +0.9%	$47.60	$33.19 ▼ $62.98	$3.68B	1.04	755,199 shs	388,606 shs
XENE Xenon Pharmaceuticals	$32.07 +0.5%	$33.05	$26.74 ▼ $46.00	$2.46B	1.09	562,628 shs	386,360 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FOLD Amicus Therapeutics	0.00%	-7.13%	-13.05%	-36.40%	-41.35%
MBX MBX Biosciences	0.00%	-4.10%	-16.83%	+30.29%	+1,027,999,900.00%
MRUS Merus	0.00%	-5.06%	+19.50%	+11.33%	-3.04%
XENE Xenon Pharmaceuticals	0.00%	-2.74%	+1.50%	-9.73%	-12.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FOLD Amicus Therapeutics	4.0182 of 5 stars	3.4	2.0	4.3	1.9	0.0	1.9
MBX MBX Biosciences	2.0723 of 5 stars	3.5	0.0	0.0	0.0	3.3	0.6
MRUS Merus	3.402 of 5 stars	4.6	3.0	0.0	3.3	1.7	0.0
XENE Xenon Pharmaceuticals	3.3417 of 5 stars	4.5	4.0	0.0	1.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FOLD Amicus Therapeutics	2.70	Moderate Buy	$16.22	187.37% Upside
MBX MBX Biosciences	3.00	Buy	$37.50	285.41% Upside
MRUS Merus	3.14	Buy	$84.64	59.51% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$54.82	70.95% Upside

Current Analyst Ratings Breakdown

Latest MBX, XENE, MRUS, and FOLD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	MRUS Merus	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
5/19/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
5/14/2025	XENE Xenon Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00
5/13/2025	XENE Xenon Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $47.00
5/13/2025	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$58.00 ➝ $55.00
5/13/2025	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $53.00
5/13/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
5/13/2025	XENE Xenon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $55.00
5/8/2025	MRUS Merus	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$91.00 ➝ $89.00
5/7/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$55.00
5/5/2025	XENE Xenon Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FOLD Amicus Therapeutics	$528.29M	3.29	N/A	N/A	$0.65 per share	8.68
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
MRUS Merus	$36.13M	101.64	N/A	N/A	$9.46 per share	5.61
XENE Xenon Pharmaceuticals	$9.43M	260.92	N/A	N/A	$9.90 per share	3.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FOLD Amicus Therapeutics	-$56.11M	-$0.09	N/A	13.13	N/A	-5.41%	4.67%	1.05%	8/14/2025 (Estimated)
MBX MBX Biosciences	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
MRUS Merus	-$215.33M	-$4.08	N/A	N/A	N/A	-506.73%	-35.99%	-29.83%	7/30/2025 (Estimated)
XENE Xenon Pharmaceuticals	-$234.33M	-$3.23	N/A	N/A	N/A	N/A	-32.44%	-30.84%	8/6/2025 (Estimated)

Latest MBX, XENE, MRUS, and FOLD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/12/2025	Q1 2025	XENE Xenon Pharmaceuticals	-$0.90	-$0.83	+$0.07	-$0.83	$1.64 million	$7.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FOLD Amicus Therapeutics	2.02	3.34	2.47
MBX MBX Biosciences	N/A	N/A	N/A
MRUS Merus	N/A	5.86	5.86
XENE Xenon Pharmaceuticals	N/A	17.66	17.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FOLD Amicus Therapeutics	N/A
MBX MBX Biosciences	N/A
MRUS Merus	96.14%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
FOLD Amicus Therapeutics	2.20%
MBX MBX Biosciences	52.19%
MRUS Merus	4.57%
XENE Xenon Pharmaceuticals	5.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FOLD Amicus Therapeutics	480	307.93 million	301.16 million	Optionable
MBX MBX Biosciences	36	33.42 million	N/A	N/A
MRUS Merus	37	69.21 million	66.05 million	Optionable
XENE Xenon Pharmaceuticals	210	76.73 million	72.50 million	Optionable

MBX, XENE, MRUS, and FOLD Headlines

Recent News About These Companies

Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Down 3.4% - Here's Why

June 16, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Recommendation of "Buy" by Brokerages

June 15, 2025 | americanbankingnews.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of "Buy" from Analysts

June 15, 2025 | marketbeat.com

Brokers Set Expectations for XENE FY2026 Earnings

June 12, 2025 | americanbankingnews.com

Traders Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)

June 12, 2025 | marketbeat.com

Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?

June 11, 2025 | zacks.com

Cantor Fitzgerald Estimates XENE FY2026 Earnings

June 10, 2025 | marketbeat.com

Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

June 3, 2025 | globenewswire.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

June 2, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Bank of America Corp DE

May 31, 2025 | marketbeat.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 30, 2025 | globenewswire.com

Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE)

May 30, 2025 | marketbeat.com

Ameriprise Financial Inc. Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 28, 2025 | marketbeat.com

Woodline Partners LP Makes New $1.57 Million Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 27, 2025 | marketbeat.com

Two Sigma Investments LP Increases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 27, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Position Lifted by Millennium Management LLC

May 26, 2025 | marketbeat.com

Northern Trust Corp Raises Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 26, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Acquired by Two Sigma Advisers LP

May 25, 2025 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Lowered by StockNews.com

May 23, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Buy" by Brokerages

May 23, 2025 | marketbeat.com

Fair Value analysis proves accurate as XENE drops 37% from February 2024 peak

May 21, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBX, XENE, MRUS, and FOLD Company Descriptions

Amicus Therapeutics NASDAQ:FOLD

$5.64 -0.09 (-1.48%)

Closing price 03:59 PM Eastern

Extended Trading

$5.64 0.00 (0.00%)

As of 04:03 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

MBX Biosciences NYSE:MBX

$9.73 -0.55 (-5.35%)

Closing price 03:59 PM Eastern

Extended Trading

$9.74 +0.00 (+0.05%)

As of 04:04 PM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Merus NASDAQ:MRUS

$53.06 +0.47 (+0.90%)

Closing price 03:59 PM Eastern

Extended Trading

$53.12 +0.06 (+0.11%)

As of 04:02 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Xenon Pharmaceuticals NASDAQ:XENE

$32.07 +0.17 (+0.52%)

Closing price 03:59 PM Eastern

Extended Trading

$32.06 0.00 (-0.01%)

As of 04:01 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time